Your browser doesn't support javascript.
loading
Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.
Pospisilova, Kristyna; Siroka, Jitka; Karaskova, Eva; Hradsky, Ondrej; Lerchova, Tereza; Zarubova, Kristyna; Copova, Ivana; Gonsorcikova, Lucie; Velganova-Veghova, Maria; Francova, Irena; Urbanek, Lubor; Geryk, Milos; Mihal, Vladimir; Bronsky, Jiri.
Afiliación
  • Pospisilova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. potuznikovakris@gmail.com.
  • Siroka J; Laboratory of Growth Regulators, Palacky University Olomouc and Institute of Experimental Botany AS CR, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
  • Karaskova E; Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, I.P. Pavlova 185/6, 779 00, Olomouc, Czech Republic.
  • Hradsky O; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
  • Lerchova T; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
  • Zarubova K; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
  • Copova I; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
  • Gonsorcikova L; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
  • Velganova-Veghova M; Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, I.P. Pavlova 185/6, 779 00, Olomouc, Czech Republic.
  • Francova I; Institute of Medical Biochemistry and Laboratory Diagnosis, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Na Bojisti 3, Prague 2, 121 08, Prague, Czech Republic.
  • Urbanek L; Laboratory of Growth Regulators, Palacky University Olomouc and Institute of Experimental Botany AS CR, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
  • Geryk M; Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, I.P. Pavlova 185/6, 779 00, Olomouc, Czech Republic.
  • Mihal V; Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, I.P. Pavlova 185/6, 779 00, Olomouc, Czech Republic.
  • Bronsky J; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic.
Paediatr Drugs ; 23(2): 183-194, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33709340
BACKGROUND: The additional value of azathioprine concomitant treatment on infliximab pharmacokinetics in children is not well described yet. AIMS: In the present study, we aimed to describe the relationship between thiopurine metabolite levels, infliximab trough levels, anti-IFX antibody formation, and clinical and laboratory markers of disease activity in pediatric patients with Crohn's disease, and to assess non-adherence. METHODS: Data were collected prospectively during repeated visits from pediatric patients followed for Crohn's disease in two Czech pediatric inflammatory bowel disease centers between January 2016 and June 2017. Thiopurine metabolites (6-thioguanine and 6-methylmercaptopurine) were measured by high-performance liquid chromatography. Infliximab trough levels and anti-IFX antibody serum levels were measured routinely by ELISA. The risk of loss of response to infliximab therapy was also assessed. RESULTS: A significant association between infliximab serum levels and 6-thioguanine erythrocyte levels was observed when tested as categorical variables (63 patients, 321 observations). To predict infliximab levels > 5 µg/mL, we propose a 6-thioguanine cutoff of 278 pmol/8 × 108 erythrocytes (sensitivity, 0.799; specificity, 0.347). A higher loss-of-response-to-infliximab rate (tested in a subgroup of 51 patients) was observed in patients with undetectable 6-thioguanine levels than in those with detectable levels (p = 0.026). Non-adherence to azathioprine therapy was suspected in 20% of patients. CONCLUSION: Thiopurine metabolite monitoring in pediatric patients with Crohn's disease is useful when optimizing combination therapy. Pediatric patients with undetectable 6-thioguanine levels are more likely to lose response to infliximab therapy. When targeting optimal infliximab levels, the 6-thioguanine cutoff levels in children appear to be higher than in adults.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azatioprina / Enfermedad de Crohn / Infliximab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Paediatr Drugs Asunto de la revista: PEDIATRIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azatioprina / Enfermedad de Crohn / Infliximab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Paediatr Drugs Asunto de la revista: PEDIATRIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Suiza